Substance P Receptor Antagonism: A Potential Novel Treatment Option for Viral-Myocarditis
المؤلفون المشاركون
Firozgary, Bahrom
Bulsara, Tushar
Taffet, George E.
Engineer, Nikita
Khumbatta, Mitra
Reynolds, Corey
Pham, Thuy
Robinson, Prema
Firozgary, Gohar
المصدر
العدد
المجلد 2015، العدد 2015 (31 ديسمبر/كانون الأول 2015)، ص ص. 1-12، 12ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2015-03-02
دولة النشر
مصر
عدد الصفحات
12
التخصصات الرئيسية
الملخص EN
Viral-myocarditis is an important cause of heart failure for which no specific treatment is available.
We previously showed the neuropeptide substance P (SP) is associated with the pathogenesis of murine myocarditis caused by encephalomyocarditis virus (EMCV).
The current studies determined if pharmacological inhibition of SP-signaling via its high affinity receptor, NK1R and downstream G-protein, Ras homolog gene family, member-A (RhoA), will be beneficial in viral-myocarditis.
Aprepitant (1.2 mg/kg), a SP-receptor antagonist, or fasudil (10 mg/kg), a RhoA inhibitor, or saline control was administered daily to mice orally for 3 days, prior to, or 5 days following, intraperitoneal infection with and without 50 PFU of EMCV, following which disease assessment studies, including echocardiogram and cardiac Doppler were performed in day 14 after infection.
Pretreatment and posttreatment with aprepitant significantly reduced mortality, heart and cardiomyocyte size, and cardiac viral RNA levels ( P < 0.05 all, ANOVA).
Only aprepitant pretreatment improved heart functions; it significantly decreased end systolic diameter, improved fractional shortening, and increased peak aortic flow velocity ( P < 0.05 all, ANOVA).
Pre- or posttreatment with fasudil did not significantly impact disease manifestations.
These findings indicate that SP contributes to cardiac-remodeling and dysfunction following ECMV infection via its high affinity receptor, but not through the Rho-A pathway.
These studies suggest that SP-receptor antagonism may be a novel therapeutic-option for patients with viral-myocarditis.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Robinson, Prema& Taffet, George E.& Engineer, Nikita& Khumbatta, Mitra& Firozgary, Bahrom& Reynolds, Corey…[et al.]. 2015. Substance P Receptor Antagonism: A Potential Novel Treatment Option for Viral-Myocarditis. BioMed Research International،Vol. 2015, no. 2015, pp.1-12.
https://search.emarefa.net/detail/BIM-1056262
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Robinson, Prema…[et al.]. Substance P Receptor Antagonism: A Potential Novel Treatment Option for Viral-Myocarditis. BioMed Research International No. 2015 (2015), pp.1-12.
https://search.emarefa.net/detail/BIM-1056262
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Robinson, Prema& Taffet, George E.& Engineer, Nikita& Khumbatta, Mitra& Firozgary, Bahrom& Reynolds, Corey…[et al.]. Substance P Receptor Antagonism: A Potential Novel Treatment Option for Viral-Myocarditis. BioMed Research International. 2015. Vol. 2015, no. 2015, pp.1-12.
https://search.emarefa.net/detail/BIM-1056262
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1056262
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر